<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709342</url>
  </required_header>
  <id_info>
    <org_study_id>CM4620-202</org_study_id>
    <nct_id>NCT03709342</nct_id>
  </id_info>
  <brief_title>A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis</brief_title>
  <official_title>A Pharmacodynamic and Pharmacokinetic Study of CM4620 Injectable Emulsion (CM4620-IE) in Patients With Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CalciMedica, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CalciMedica, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study will evaluate the pharmacodynamic and pharmacokinetic profile of&#xD;
      CM4620-IE in patients with acute pancreatitis. The first five (5) patients will receive ≤&#xD;
      2.08 mg/kg of CM4620-IE by continuous IV infusion on Day 1. If necessary, up to an additional&#xD;
      4 patients may be treated at a different dose of CM4620-IE as determined by the obtained PK&#xD;
      and PD data. The infusion of CM4620-IE will start within 12 hours from the time the patient&#xD;
      or LAR provides informed consent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2019</start_date>
  <completion_date type="Actual">June 7, 2019</completion_date>
  <primary_completion_date type="Actual">March 7, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in IL-2 production</measure>
    <time_frame>30 days</time_frame>
    <description>The change in IL-2 production by stimulated T-lymphocytes from prior to the administration of CM4620-IE, and after completion of CM4620-IE administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>30 days</time_frame>
    <description>The number of participants who experience treatment-emergent adverse events (TEAEs) with Investigator-specified relationship to CM4620-IE and assessment of severity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>All Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM4620-IE</intervention_name>
    <description>single IV infusion on Day 1 over 4 hours</description>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of acute pancreatitis established by the presence of abdominal pain&#xD;
             consistent with acute pancreatitis, and 1 of the following 2 criteria:&#xD;
&#xD;
               1. Serum lipase and/or serum amylase &gt; 3 times the upper limit of normal (ULN);&#xD;
&#xD;
               2. Characteristic findings of acute pancreatitis on abdominal imaging;&#xD;
&#xD;
          2. Adults ≥ 18 years of age;&#xD;
&#xD;
          3. A female patient of child-bearing potential who is sexually active with a male partner&#xD;
             must be willing to practice acceptable methods of birth control for 365 days after the&#xD;
             last dose of CM4620-IE;&#xD;
&#xD;
          4. A male patient who is sexually active with a female partner of childbearing potential&#xD;
             must be willing to practice acceptable methods of birth control for 365 days after the&#xD;
             last dose of CM4620-IE and must not donate sperm for 365 days;&#xD;
&#xD;
          5. Willing and able to, or have a legal authorized representative (LAR) who is willing&#xD;
             and able to, provide informed consent to participate, and cooperate with all aspects&#xD;
             of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any concurrent clinical condition that a study physician believes could potentially&#xD;
             pose an unacceptable health risk to the patient while involved in the study or may&#xD;
             limit expected survival to &lt; 6 months;&#xD;
&#xD;
          2. Suspected presence of cholangitis in the judgment of the treating investigator;&#xD;
&#xD;
          3. Any malignancy being treated with chemotherapy or immunotherapy;&#xD;
&#xD;
          4. Any autoimmune disease being treated with immunosuppressive medication or&#xD;
             immunotherapy (Section 5.3 for list of prohibited medications);&#xD;
&#xD;
          5. History of:&#xD;
&#xD;
               1. Chronic pancreatitis, pancreatic necrosectomy, or pancreatic enzyme replacement&#xD;
                  therapy;&#xD;
&#xD;
               2. Biopsy proven cirrhosis, portal hypertension, hepatic failure/hepatic&#xD;
                  encephalopathy;&#xD;
&#xD;
               3. Known hepatitis B or C, or HIV;&#xD;
&#xD;
               4. History of organ or hematologic transplant;&#xD;
&#xD;
               5. Myocardial infarction, revascularization, cardiovascular accident (CVA) in the 30&#xD;
                  days prior to Day 1;&#xD;
&#xD;
          6. Current renal replacement therapy;&#xD;
&#xD;
          7. Current known abuse of cocaine or methamphetamine;&#xD;
&#xD;
          8. Known to be pregnant or are nursing;&#xD;
&#xD;
          9. Participated in another study of an investigational drug or therapeutic medical device&#xD;
             in the 30 days prior to Day 1;&#xD;
&#xD;
         10. History of allergy to eggs or known hypersensitivity to any components of CM4620-IE;&#xD;
&#xD;
         11. Prior treatment with CM4620-IE.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudarshan Hebbar, MD</last_name>
    <role>Study Director</role>
    <affiliation>CalciMedica, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 10, 2021</submitted>
    <returned>June 2, 2021</returned>
    <submitted>August 2, 2021</submitted>
    <returned>August 24, 2021</returned>
    <submitted>October 12, 2021</submitted>
    <returned>October 12, 2021</returned>
    <submitted>October 15, 2021</submitted>
    <returned>November 11, 2021</returned>
    <submitted>November 17, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

